GeoVax Aligns Vaccine Pipeline with New U.S. Global Health Strategy

GeoVax Labs, Inc. announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio. The clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers stated that its pipeline directly aligns with the policy's pillars of making America safer, stronger, and more prosperous. The strategy emphasizes American innovation, domestic pharmaceutical manufacturing, and global partnerships in strengthening health security and safeguarding U.S. national interests.

GeoVax's pipeline includes its Mpox/Smallpox vaccine (GEO-MVA), next-generation multi-antigen COVID-19 vaccine (GEO-CM04S1), and other infectious disease vaccines in development that intersect with the vast majority of strategic initiatives outlined in the new health strategy. The company is rapidly developing a continuous cell-line (AGE1) manufacturing technology which will enhance scalability, speed, and resilience, addressing longstanding supply chain vulnerabilities in U.S. biodefense. This advanced manufacturing process makes GeoVax's MVA-based platform uniquely suited for rapid vaccine response against infectious disease threats including Mpox, smallpox, Zika, and hemorrhagic fever viruses.

The company's GEO-MVA program for Mpox and smallpox recently received favorable EMA scientific advice recommending an expedited regulatory pathway via an immuno-bridging study. This regulatory guidance provides a potentially faster path to approval and significantly accelerates GeoVax's commercialization and revenue opportunities. The program will serve as the cornerstone of the company's strategy to develop regional supply capabilities ensuring timely and equitable access to vaccines worldwide. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.

GeoVax is positioned as a U.S.-based alternative to the existing foreign monopoly in poxvirus vaccines, supporting national security priorities while strengthening U.S. competitiveness in emerging global health markets. The America First strategy emphasizes leveraging U.S. foreign assistance procurements to expand global access to American-made health solutions, creating significant opportunities for domestic biotechnology companies to contribute to global health security while advancing American economic interests.

With the strategy calling for bilateral health agreements and integration with local health systems, GeoVax's multi-antigen vaccine design offers other countries efficient, cost-effective solutions that reduce dependency on fragmented, siloed programs. The company's approach directly complements U.S. goals of building resilient, country-led health systems through partnerships that strengthen global health infrastructure while promoting American technological leadership.

David Dodd, Chairman & CEO of GeoVax, stated that the America First Global Health Strategy represents a historic opportunity to align U.S. innovation with global health needs in a way that strengthens America's leadership while protecting citizens and the economy. The company's vaccine and immunotherapy programs deliver innovation, security, and scalability that support the strategy's objectives of making America safer, stronger, and more prosperous while saving lives around the world. This alignment between corporate mission and national health strategy creates significant potential for advancing both public health objectives and American economic competitiveness in the global biotechnology sector.